You are here

GENOMAS, INC.

Company Information
Address
67 JEFFERSON ST
HARTFORD, CT 06106
United States



Information

UEI: N/A

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. System for DNA-Guided Optimization and Personalization of Statin Therapy

    Amount: $1,250,027.00

    DESCRIPTION (provided by applicant): Currently 30 million Americans with elevated cholesterol receive statin therapy, making statins the most prescribed drug class in the U.S. Statin Induction and Neu ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  2. MRI DNA Biomarkers for Neuropsychiatric Disease

    Amount: $1,349,950.00

    DESCRIPTION (provided by applicant): Schizophrenia (SZ) is a severely debilitating mental illnesses. It is highly heritable, with concordance rates of 50-80% in monozygotic twins and substantial famil ...

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
  3. DNA Diagnostic System for Statin Safety and Efficacy

    Amount: $143,338.00

    DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  4. DNA Diagnostic System for Statin Safety and Efficacy

    Amount: $1,008,599.00

    DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic ...

    SBIRPhase II2008Department of Health and Human Services National Institutes of Health
  5. DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

    Amount: $449,182.00

    DESCRIPTION (provided by applicant): Atypical antipsychotic drugs (AAPs) are indicated in the treatment for schizophrenia, bipolar disorder, psychotic depression and other psychiatric disorders. Their ...

    SBIRPhase II2007Department of Health and Human Services National Institutes of Health
  6. Physiogenomic Arrays for Clinical Neuropsychiatry

    Amount: $400,000.00

    DESCRIPTION (provided by applicant): Neuropsychiatric and neurodegenerative disorders such as schizophrenia, Alzheimer's disease, and depression are genetically complex diseases with multiple contribu ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  7. Gene Markers: Antipsychotic-Induced Metabolic Syndrome

    Amount: $107,000.00

    DESCRIPTION (PROVIDED BY APPLICANT): This Phase I SBIR Program will develop genetic diagnostic products to improve the safety of atypical antipsychotics (e.g. olanzapine) for treating psychiatric diso ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government